economybharat.com

We Can Cover You
Click here
Facebook Youtube Instagram Linkedin
13
13

Approval

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis OG_NewsReleaseCompanyLogo_92873.jpg

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

creativebharatgroup@gmail.com December 14, 2024
Zug, Switzerland:   Ad hoc announcement pursuant to Art. 53 LR   ...
Read More Read more about Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union OG_NewsReleaseCompanyLogo_92866.jpg

CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union

creativebharatgroup@gmail.com December 13, 2024
Zug, Switzerland:   Atopic dermatitis is a common, chronic, and flaring inflammatory...
Read More Read more about CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union
ExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer

ExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer

creativebharatgroup@gmail.com December 2, 2024
Hørsholm, Denmark, 2 December 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies...
Read More Read more about ExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer
The board of Peptonic resolves, subject to the approval a subsequent general meeting, on a rights issue of units of approximately SEK 26.5 million

The board of Peptonic resolves, subject to the approval a subsequent general meeting, on a rights issue of units of approximately SEK 26.5 million

creativebharatgroup@gmail.com November 29, 2024
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE...
Read More Read more about The board of Peptonic resolves, subject to the approval a subsequent general meeting, on a rights issue of units of approximately SEK 26.5 million
Noble Corporation plc announces approval of request for removal from trading and official listing on Nasdaq Copenhagen

Noble Corporation plc announces approval of request for removal from trading and official listing on Nasdaq Copenhagen

creativebharatgroup@gmail.com November 18, 2024
  SUGAR LAND, TEXAS, Nov. 18, 2024 /PRNewswire/ – Noble Corporation plc (“Noble“,...
Read More Read more about Noble Corporation plc announces approval of request for removal from trading and official listing on Nasdaq Copenhagen
Uptime Launches Enhanced M&O Stamp of Approval to Accelerate Improvements in Data Center Operational Resiliency OG_NewsReleaseCompanyLogo_92359.jpg

Uptime Launches Enhanced M&O Stamp of Approval to Accelerate Improvements in Data Center Operational Resiliency

creativebharatgroup@gmail.com November 7, 2024
New York, United States:   Uptime Institute today announced its newly enhanced, market-leading,...
Read More Read more about Uptime Launches Enhanced M&O Stamp of Approval to Accelerate Improvements in Data Center Operational Resiliency